Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation

Journal of Thoracic Oncology

Volumn 7, Issue 8, 2012, Pages 1218-1227

  Tsai, Chun Ming ^a,b   Chiu, Chao Hua ^a,b,c   Chang, Kao Ting ^a   Chen, Jen Ting ^a   Lai, Chun Liang ^a,d,e,f   Chen, Yuh Min ^c   Hsiao, Shih Yin ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Georgetown Univ School of Medicine   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

^f NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Antimicrotubule agent; Gefitinib; Nonsmall cell lung cancer; P glycoprotein; Synergism

Indexed keywords

ABC TRANSPORTER; ANTIMITOTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NAVELBINE; PACLITAXEL;

ARTICLE; CANCER CELL; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG POTENTIATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE;

EID: 84863837004     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318258cf17     Document Type: Article

References (35)

1. Kelly K Huang C. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol 2008;3:664-673.
2. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
3. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
4. Herbst RS, Prager D, Hermann R, et al.; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
5. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
6. Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7:385-388.
7. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
8. Janne PA, Wang XF, Socinski MA, et al. Randomized phase II trial of erlotinib alone or in combination with carboplatin/paclitaxel in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 2010;28:155 (abstr 7503).
9. Tsai CM, Chen JT, Stewart DJ, et al. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? J Thorac Oncol 2011;6:559-568.
10. Hirsch FR, Kabbinavar F, Eisen T, et al. A randomized, phase II, biomarker- selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2011;29:3567-3573.
11. Szakcs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-137.
12. Nakamura Y, Oka M, Soda H, et al. Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65:1541-1546.
13. Yang CH, Huang CJ, Yang CS, et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 2005;65:6943-6949.
14. Leggas M, Panetta JC, Zhuang Y, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66:4802-4807.
15. Thomas H Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10:159-165.
16. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5:30.
17. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005;116:824-829.
18. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424.
19. Gazdar AF, Kadoyama C, Venzon D, et al. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monographs 1992;13:191-196.
20. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-20937.
21. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-11932.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
23. Tsai CM, Gazdar AF, Perng RP, Kramer BS. Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. Int J Cancer 1991;47:401-407.
24. Tsai CM, Hsiao SH, Frey CM, et al. Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. Cancer Res 1993;53:1079-1084.
25. Tsai CM, Levitzki A, Wu LH, et al. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res 1996;56:1068-1074.
26. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 1977;28:1-18.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
28. Stewart DJ, Raaphorst GP, Yau J, Beaubien AR. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 1996;14:115-130.
29. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31.
30. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302.
31. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279.
32. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-7241.
33. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753.
34. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
35. Tsai CM, Chang KT, Chiu CH, et al. The synergistic effects between gefitinib and anti-microtubule agents in non-small-cell lung cancer cells and selected patients. J Thoracic Oncol 2009;4:S555 (suppl 19; abstr PD10.3.5)